Filing Details
- Accession Number:
- 0000950170-24-063262
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-21 21:00:31
- Reporting Period:
- 2024-05-17
- Accepted Time:
- 2024-05-21 21:00:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 899460 | Mannkind Corp | MNKD | Pharmaceutical Preparations (2834) | 133607736 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1297976 | David Thomson | 1 Casper Street Danbury CT 06810 | Evp Genl Counsel & Secretary | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par Value | Acquisiton | 2024-05-17 | 77,420 | $4.59 | 989,866 | No | 4 | A | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2024-05-17 | 85,797 | $4.59 | 904,069 | No | 4 | F | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2024-05-18 | 6,916 | $4.59 | 897,153 | No | 4 | F | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2024-05-21 | 23,537 | $4.66 | 873,616 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Footnotes
- A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 156,420 shares. The acquisition of 79,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021.
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
- Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023.
Billionaire Hedge Funds
